Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Income from Continuing Operations (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Income from Continuing Operations for 5 consecutive years, with 19881000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 75.8% year-over-year to 19881000.0, compared with a TTM value of 24193000.0 through Dec 2025, up 81.56%, and an annual FY2025 reading of 24193000.0, up 81.56% over the prior year.
  • Income from Continuing Operations was 19881000.0 for Q4 2025 at Aligos Therapeutics, up from 31537000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 43088000.0 in Q1 2025 and bottomed at 82150000.0 in Q4 2024.
  • Average Income from Continuing Operations over 5 years is 23372950.0, with a median of 22420500.0 recorded in 2022.
  • Peak annual rise in Income from Continuing Operations hit 223.59% in 2025, while the deepest fall reached 413.44% in 2025.
  • Year by year, Income from Continuing Operations stood at 37714000.0 in 2021, then soared by 41.97% to 21886000.0 in 2022, then fell by 27.44% to 27892000.0 in 2023, then plummeted by 194.53% to 82150000.0 in 2024, then skyrocketed by 75.8% to 19881000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ALGS at 19881000.0 in Q4 2025, 31537000.0 in Q3 2025, and 15863000.0 in Q2 2025.